SURMOUNT-REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity.

What Was Tested

The paper reports a study of Tirzepatide, published as a randomized controlled trial.

Who Took Part

The abstract describes 3000 participants taking part.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

A 5-year, phase 4, multicenter, open-label, pragmatic randomized clinical trial is enabled through access to participants' integrated electronic healthcare record data.

The study will enroll approximately 3000 participants from Greater Manchester, UK, who are randomly assigned in a 1:1 ratio to receive either tirzepatide and SoC or SoC alone.

How the Study Was Run

The researchers set it up as a randomized, open-label and multicenter study.

The participants were allocated by chance, so the Tirzepatide group and the comparison group should start out alike.

Nothing was hidden in this open-label Tirzepatide study: the participants and staff both knew the treatment.

Running at several centres spread the Tirzepatide study over different clinics and patient groups.

What Was Measured

Topics PubMed links to this paper include Tirzepatide, Obesity, United Kingdom, Diabetes Mellitus, Type 2, Quality of Life, Anti-Obesity Agents and Primary Health Care.

Author keywords: electronic health records, pragmatic trial, primary care and type 2 diabetes incidence.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Tirzepatide in 3000 participants.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (Obesity (Silver Spring, Md.)), a journal based in United States.

More context: the Tirzepatide compound page, all human trials.